Trials / Completed
CompletedNCT00913198
A Study of CP-4126 in Patients With Advanced Pancreatic Cancer
A Phase II Study of CP-4126 in Patients With Advanced Pancreatic Cancer.
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 21 (actual)
- Sponsor
- Clavis Pharma · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The main objective of this study is to assess the biological activity of CP-4126 in patients with advanced pancreatic cancer. In addition, the correlation between hENT1 (human equilibrative nucleoside transporter 1) and overall survival will be studied.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | IV CP-4126 | 1250 mg/m2/d, IV (in the vein) on day 1, 8 and 15 of each 4 week cycle. Number of Cycles: until progression or unacceptable toxicity develops. |
Timeline
- Start date
- 2009-04-01
- Primary completion
- 2011-06-01
- Completion
- 2011-09-01
- First posted
- 2009-06-04
- Last updated
- 2012-02-10
Locations
3 sites across 2 countries: Belgium, Norway
Source: ClinicalTrials.gov record NCT00913198. Inclusion in this directory is not an endorsement.